Acurx Pharmaceuticals, Inc.
ACXPAcurx Pharmaceuticals is a late-stage biopharmaceutical company dedicated to developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections.
Table of contents
Earnings
Next report
Aug 14, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Acurx Pharmaceuticals is a late-stage biopharmaceutical company dedicated to developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company utilizes a proprietary Gram-positive selective spectrum (GPSS) approach to target the DNA polymerase IIIC enzyme, a previously unexploited mechanism of action designed to inhibit DNA replication and cause bacterial cell death. Their primary value proposition lies in addressing the global antimicrobial resistance crisis by developing treatments that preserve the healthy gut microbiome while eradicating priority pathogens.
Acurx is a pioneer in DNA polymerase IIIC inhibition, currently advancing the first antibiotic candidate of this class into Phase 3 clinical trials.
Questions, answered.
- What is Acurx Pharmaceuticals, Inc.'s market cap?
- Acurx Pharmaceuticals, Inc. (ACXP) has a market capitalization of $6.1M and trades on NASDAQ.
- Who are Acurx Pharmaceuticals, Inc.'s competitors?
- Acurx Pharmaceuticals, Inc.'s key competitors include Merck & Co., Viatris, Spero Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Acurx Pharmaceuticals, Inc. partner with?
- Acurx Pharmaceuticals, Inc.'s notable partners include GLSynthesis Inc., University of Houston.
- Where is Acurx Pharmaceuticals, Inc. headquartered?
- Acurx Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 4 people. It has been publicly traded since 2021.